Recombinant human C1 esterase inhibitor vs placebo or active control
Adverse events(during · children or adults with Types I or II HAE
Recombinant human C1 esterase inhibitor showed no clear difference in adverse events(during compared with placebo or active control (low certainty).
1 finding from 1 review
- Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes onlyRR 1.39 [0.71, 2.7]1 study · 29 participantsLow